Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
boston
2
×
boston blog main
boston top stories
deals
life sciences
national blog main
national top stories
new york blog main
san francisco blog main
azacitidine
beta-thalassemia
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
dacogen
daniel o'day
decitabine
dna
epigenetics
epizyme
farydak
fda
flagship pioneering
foundation medicine
foundationone cdx
foundationone heme
fulcrum therapeutics
genentech
insulated genomic domains
kaleido biosciences
mahesh karande
new york top stories
omega therapeutics
osimertinib
panobinostat
richard young
robert gould
roche
What
morning
2
×
acquire
agreed
aims
approach
based
big
billion
biotech
broad
called
confidence
debuts
developing
didn’t
drugs
epigenetic
epigenetics
field
flagship’s
foundation
gain
genentech
medicine
medicines
momentum
new
omega
panels
pay
pays
picked
profiling
recently
redux
remaining
research
rest
roche
share
Language
unset
Current search:
morning
×
boston
×
biotech
×
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine